| The safety of vedolizumab for ulcerative colitis and Crohn's disease JF Colombel, BE Sands, P Rutgeerts, W Sandborn, S Danese, G D'Haens, ... Gut 66 (5), 839-851, 2017 | 823 | 2017 |
| Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis BE Sands, L Peyrin-Biroulet, EV Loftus Jr, S Danese, JF Colombel, ... New England Journal of Medicine 381 (13), 1215-1226, 2019 | 607 | 2019 |
| An overview of the mechanism of action of the monoclonal antibody vedolizumab T Wyant, E Fedyk, B Abhyankar Journal of Crohn's and Colitis 10 (12), 1437-1444, 2016 | 280 | 2016 |
| Long-term efficacy of vedolizumab for ulcerative colitis EV Loftus Jr, JF Colombel, BG Feagan, S Vermeire, WJ Sandborn, ... Journal of Crohn's and Colitis 11 (4), 400-411, 2017 | 230 | 2017 |
| Long-term efficacy of vedolizumab for Crohn’s disease S Vermeire, EV Loftus Jr, JF Colombel, BG Feagan, WJ Sandborn, ... Journal of Crohn's and Colitis 11 (4), 412-424, 2017 | 224 | 2017 |
| Efficacy of vedolizumab induction and maintenance therapy in patients with ulcerative colitis, regardless of prior exposure to tumor necrosis factor antagonists BG Feagan, DT Rubin, S Danese, S Vermeire, B Abhyankar, S Sankoh, ... Clinical Gastroenterology and Hepatology 15 (2), 229-239. e5, 2017 | 218 | 2017 |
| Vedolizumab as induction and maintenance therapy for Crohn's disease in patients naïve to or who have failed tumor necrosis factor antagonist therapy BE Sands, WJ Sandborn, G Van Assche, M Lukas, J Xu, A James, ... Inflammatory bowel diseases 23 (1), 97-106, 2017 | 185 | 2017 |
| Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease U Mahadevan, S Vermeire, K Lasch, B Abhyankar, F Bhayat, A Blake, ... Alimentary pharmacology & therapeutics 45 (7), 941-950, 2017 | 135 | 2017 |
| Efficacy and safety of vedolizumab in ulcerative colitis and Crohn’s disease patients stratified by age V Yajnik, N Khan, M Dubinsky, J Axler, A James, B Abhyankar, K Lasch Advances in therapy 34, 542-559, 2017 | 101 | 2017 |
| Development of gut-selective pan-Janus kinase inhibitor TD-1473 for ulcerative colitis: a translational medicine programme WJ Sandborn, DD Nguyen, DT Beattie, P Brassil, W Krey, J Woo, E Situ, ... Journal of Crohn's and Colitis 14 (9), 1202-1213, 2020 | 64 | 2020 |
| OP34 VARSITY: a double-blind, double-dummy, randomised, controlled trial of vedolizumab versus adalimumab in patients with active ulcerative colitis S Schreiber, L Peyrin-Biroulet, EV Loftus Jr, S Danese, JF Colombel, ... Journal of Crohn's and Colitis 13 (Supplement_1), S612-S613, 2019 | 46 | 2019 |
| 416a–Vedolizumab shows superior efficacy versus adalimumab: results of Varsity—the first head-to-head study of biologic therapy for moderate-to-severe ulcerative colitis BE Sands, L Peyrin-Biroulet, EV Loftus, S Danese, JF Colombel, ... Gastroenterology 156 (6), S-81, 2019 | 29 | 2019 |
| Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease M Dubinsky, U Mahadevan, S Vermeire, B Abhyankar, K Lasch Journal of Crohns & Colitis 9, S361-S362, 2015 | 27 | 2015 |
| Sa1271 efficacy of vedolizumab with concomitant corticosteroid or immunomodulator use in patients with ulcerative colitis from GEMINI 1 JF Colombel, EV Loftus, CA Siegel, J Lewis, MD Smyth, S Sankoh, ... Gastroenterology 148 (4), S-277-S-278, 2015 | 23 | 2015 |
| P-105 The Effect of Vedolizumab on Extraintestinal Manifestations in Patients with Crohn's Disease in GEMINI 2 D Rubin, B Feagan, G Dryden, G Melmed, K Lasch, B Abhyankar, J Xu, ... Inflammatory Bowel Diseases 22, S42-S43, 2016 | 15 | 2016 |
| Sa1261 Vedolizumab for the Treatment of Fistulizing Crohn's Disease: An Exploratory Analysis of Data From GEMINI 2 BG Feagan, DA Schwartz, S Danese, DT Rubin, B Abhyankar, MD Smyth, ... Gastroenterology 148 (4), S-274, 2015 | 15 | 2015 |
| Relationship between vedolizumab pharmacokinetics and endoscopic outcomes in patients with ulcerative colitis M Rosario, B Abhyankar, S Sankoh, N Dirks, K Lasch, W Sandborn JOURNAL OF CROHNS & COLITIS 9, S46-S46, 2015 | 15 | 2015 |
| Long-Term Efficacy of Vedolizumab Therapy for Patients With Ulcerative Colitis: Presidential Poster: 1616 B Feagan, A Kaser, M Smyth, R Panaccione, S Sankoh, B Abhyankar Official journal of the American College of Gastroenterology| ACG 109, S477-S478, 2014 | 13 | 2014 |
| Long-Term Efficacy of Vedolizumab Therapy for Patients With Ulcerative Colitis: Presidential Poster: 1616 B Feagan, A Kaser, M Smyth, R Panaccione, S Sankoh, B Abhyankar Official journal of the American College of Gastroenterology| ACG 109, S477-S478, 2014 | 13 | 2014 |
| Challenges and opportunities in IBD clinical trial design MC Dubinsky, R Collins, MT Abreu, V Jairath, JD Lewis, J Lindsay, ... Gastroenterology 161 (2), 400-404, 2021 | 12 | 2021 |
William SandbornUniversity of California San Diego在 ucsd.edu 的電子郵件地址已通過驗證
